Portfolio Analysis in Amsterdam.

A patent portfolio analysis Amsterdam founders and IP counsel can take to a board, an investor or a licensing table has to start where the value actually sits — in payment rails, recommendation engines, adtech pipelines and the life-science files now clustering around the European Medicines Agency. Amsterdam is one of Europe’s top five startup ecosystems and its premier fintech hub, home to Adyen, Mollie, Booking.com, Picnic and the EMEA headquarters of Google, Netflix and Uber. That software-and-services centre of gravity makes the questions asked of a portfolio here commercial and technical at once.

The work is landscape, gap, strength and valuation analysis — not litigation. It is the diligence behind a Series C raise, the freedom-to-operate read before a payments launch, and the renewal-fee decision that stops a growing estate quietly overspending. PerspireIP delivers that read for the scale-up founders, in-house counsel and deal teams running Amsterdam portfolios.

Why patent portfolio analysis Amsterdam teams start with software and services

In a fab town a portfolio review starts with the process. In Amsterdam it starts with the codebase, the data pipeline and the business model. This is a software-first economy: fintech and payments around Adyen, Mollie, Bunq and the wider PSD2 ecosystem; marketplaces and travel-tech around Booking.com and Picnic; adtech, martech and SaaS across the canal-belt scale-ups; and a fast-growing AI cluster anchored by Amsterdam Science Park, the University of Amsterdam and events such as World Summit AI. The intellectual property that matters here is rarely a single blocking patent — it is a thin, fast-moving layer of computer-implemented inventions, algorithms and data methods.

That setting changes what a study must deliver. A landscape map is not academic — it is an exhibit in a funding round or an M&A data room. A strength score is not a curiosity — it is a number that a growth investor’s technical diligence will test. We build a patent portfolio analysis Amsterdam corporate-development teams, investment committees and general counsel can act on, tied to the raise, the deal or the launch that prompted it.

• Venture and growth-equity diligence — ownership chain, inventor assignments and product coverage of a scale-up’s Dutch and European patents
• M&A and secondary deals — what the target’s IP genuinely protects, and what is merely filed, before the term sheet is signed
• Freedom-to-operate before launch — which third-party patents read on a new payments, marketplace or adtech feature
• Board and budget reviews — a periodic strength, gap and renewal-cost picture for the CFO and general counsel

The Dutch registration patent means analysis, not the grant, proves strength

A Dutch national patent is granted very differently from a U.S. or examined European one, and that changes how you must read the estate. The Netherlands runs a registration system: Octrooicentrum Nederland, part of the RVO, performs only a novelty search and grants the patent once the formalities are met — regardless of what that search finds. There is no substantive examination of novelty or inventive step before grant.

The practical consequence is stark. A granted Dutch registration patent — a registratieoctrooi — tells you almost nothing about whether its claims would survive. Validity is genuinely tested only later, in court or by the analysis a buyer’s or investor’s counsel will run. An estate that looks impressive on a grant count can be thin once the prior art is laid against the claims, and a founder who has never had the portfolio analysed simply does not know which side of that line each asset falls on.

This is why a patent portfolio analysis Amsterdam owners commission matters more in the Netherlands than in examined jurisdictions, not less. It is a common and expensive surprise: a scale-up enters a raise or a sale believing it holds twenty granted Dutch patents, only to find that a fraction would withstand a serious validity attack — while the counterparty has already run exactly that analysis.

There is also a reform on the horizon that owners should plan around. The Dutch government is overhauling the Rijksoctrooiwet to replace the registration patent with a genuinely examined patent: the Netherlands Patent Office would assess novelty, inventive step and sufficiency before grant, and direct PCT national-phase entry would open. Expected around 2028, it is the biggest change to the Dutch system in decades — and it makes the current registered estate, granted without examination, exactly the part of a portfolio worth grading now.

Reading a software, fintech and data-driven estate

Software and fintech portfolios behave nothing like a semiconductor or pharma estate. The inventions are computer-implemented, the product cycle is measured in sprints, and the patents sit close to the European Patent Office’s eligibility line for computer-implemented inventions — where a claim must solve a technical problem in a technical way to survive. Reading such an estate means separating the claims that clear that bar from the ones a challenger would knock out as an abstract business method.

The strategic questions are also different. For a payments or marketplace company the real risk is rarely one blocking patent; it is freedom to operate across a crowded field of process and data-handling filings, and the exposure to standard-essential patents in connectivity, video and payment interfaces. We map what you own against what you are exposed to, and grade whether each key filing actually reads on the technical contribution the EPO rewards.

• Eligibility grading — which computer-implemented claims clear the EPO’s technical-character test and which read as an unpatentable business method
• Freedom-to-operate mapping — the third-party patents that read on a payments, adtech or marketplace feature before you ship it
• Standard-essential exposure — the connectivity, codec and payment-interface standards your product implements, as liability and as asset
• Trade-secret boundary — where an algorithm or data method is better held as a secret than disclosed in a thin, easily-challenged patent

The Hague’s exclusive jurisdiction and the UPC Local Division

Portfolio risk is partly forum risk, and in the Netherlands the forum is unusually concentrated. The District Court of The Hague (Rechtbank Den Haag) holds exclusive national jurisdiction over Dutch patent infringement and validity disputes, with appeals to the Hague Court of Appeal (Gerechtshof Den Haag). There is no regional patchwork: every Dutch patent case is decided by one specialist court with a dedicated patent bench, so an Amsterdam portfolio can be graded against a single, coherent body of case law less than an hour down the road.

The Hague is also famous for speed and reach. Its kort geding summary proceedings can deliver a preliminary injunction in a matter of months on a showing that the patent is likely valid and likely infringed — one of the fastest interim remedies in Europe. And since the 1989 Lincoln v Interlas judgment, Dutch courts have granted cross-border injunctions reaching beyond national borders, making The Hague a genuine pan-European enforcement venue rather than a domestic one.

Since June 2023 the same city hosts a Local Division of the Unified Patent Court. The UPC Local Division in The Hague hears infringement and revocation actions on European patents with unitary effect and on classical European patents that have not been opted out, in a multinational three-judge panel drawing on the same deep Dutch patent expertise. For a portfolio owner that means overlapping systems to plan for: a Dutch registration patent enforced only in The Hague under Dutch law, and a European patent that may now be litigated — or revoked — centrally across member states at once. We flag which of your assets sit in which system, and which are most exposed to a fast, pan-European action.

The EMA effect: pharma, biotech and SPC strategy in Amsterdam

Amsterdam gained a second, very different IP centre of gravity when the European Medicines Agency relocated from London to the city in 2019 after Brexit. The EMA’s presence has pulled regulatory-affairs teams, life-science consultancies and pharma and biotech ventures into the Amsterdam orbit, and for those companies the portfolio question is not eligibility — it is term. A medicine’s commercial life is governed as much by supplementary protection certificates and regulatory exclusivity as by the base patent.

A supplementary protection certificate extends patent-like protection for up to five years beyond a medicine’s basic patent, running from the first EU marketing authorisation, with a further six-month paediatric extension available. For a pharma or biotech estate the value sits in when each SPC and exclusivity period actually expires — the moment generics or biosimilars can enter. A portfolio analysis that ignores the SPC layer misreads the estate entirely.

We build that timeline into the study for life-science clients: base-patent term, SPC term and paediatric extension per product, national validations across the EU, and the coming unitary SPC that the EU has proposed to sit alongside the unitary patent. The result is a genuine exclusivity map — the one number a licensing partner, an investor or a board actually needs from an EMA-adjacent portfolio.

Landscape, gap analysis and the unitary patent decision

The offensive side of portfolio work is finding what you do not yet own. A landscape maps the patents held by you and your competitors across a technology area; a gap or white-space analysis then shows where protectable, commercially useful inventions sit unclaimed — the ground your R&D leaders should file into before a rival does. In a scale-up racing between funding rounds, that intelligence steers a filing budget that cannot afford to be wasted.

The Amsterdam field is legible because the leaders are visible: payments and fintech around Adyen, Mollie and Bunq; travel and marketplaces around Booking.com; grocery and logistics around Picnic; and the AI research pouring out of the University of Amsterdam, VU Amsterdam and Amsterdam Science Park. Mapping filing trends across those assignees shows not just where the white space lies but where each competitor is heading — intelligence a filing programme can actually steer by.

The renewal side adds a second lever. Since 2023 a granted European patent can take unitary effect — a single renewal fee covering all participating states, priced at roughly the cost of renewing in four countries — or follow the classical route of national validations the owner can prune country by country. Which route is cheaper depends entirely on how many countries an asset truly needs, and that is a portfolio question we model per family so the renewal budget matches the commercial footprint.

• Competitive landscape maps — who holds what across your technology space, by assignee, claim scope and filing trend
• Gap and white-space analysis — the unclaimed, protectable ground to direct the next filing programme
• Renewal-fee pruning — scoring each asset against product coverage, competitive value and resale value before its next fee falls due
• Unitary-versus-classical modelling — both renewal paths priced per family against your commercial footprint

How PerspireIP builds a portfolio analysis you can act on

Every engagement follows the same disciplined path, scaled to whether you are prepping a data room, defending a valuation or planning a launch. We inventory the portfolio, verify legal status and ownership, map each asset to products and competitors, grade strength and validity exposure, and price the estate for the transaction or decision that prompted the review.

• Full inventory with legal-status, term and renewal timeline for every Dutch, European and unitary asset
• Product-to-patent coverage mapping and a claim-strength score across the estate
• EPO eligibility grading for computer-implemented inventions, and validity grading of significant assets against the prior art
• Freedom-to-operate and standard-essential exposure maps for payments, marketplace and adtech products
• SPC and exclusivity timelines for EMA-adjacent life-science estates, with the proposed unitary SPC factored in
• Renewal-fee pruning tied to your next Octrooicentrum Nederland and EPO windows, with a unitary-versus-classical model, delivered as data-room-ready exhibits

We work alongside your in-house IP team, corporate-development group or outside counsel as a specialist analysis partner, deliver to your deal or budget calendar, and keep every engagement confidential. Whether you need a one-time diligence study before an Amsterdam raise or acquisition, an annual portfolio health check for the board, or an ongoing landscaping and pruning programme, we scale to fit. Send us the assignee name or a patent list and we will scope a patent portfolio analysis Amsterdam project within one business day.

IP Landscape & Resources in Amsterdam

Key intellectual-property authorities and venues relevant to Amsterdam:

• Octrooicentrum Nederland (Netherlands Patent Office, RVO) — grants Dutch registration patents after a novelty search only, with no substantive examination, so an estate's true strength is revealed by analysis rather than by the grant
• District Court of The Hague (Rechtbank Den Haag) — holds exclusive national jurisdiction over Dutch patent infringement and validity, is known for fast kort geding injunctions and cross-border relief, with appeals to the Hague Court of Appeal
• Unified Patent Court (UPC) — operates the Local Division in The Hague, which hears infringement and revocation actions on unitary and non-opted-out European patents across the member states
• European Patent Office (EPO) — grants European and unitary patents, sets the eligibility bar for computer-implemented inventions, and publishes the filing data behind landscape, gap and renewal-versus-unitary decisions

Request a Patent Portfolio Analysis in Amsterdam

Explore related PerspireIP services: Patent Portfolio Analysis services · IP services in the Netherlands · patent invalidation · prior art search · patent landscape analysis.

Frequently Asked Questions